Capula Management’s AstraZeneca AZN Stock Holding History

Capula Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$172K	Buy	905 +743	+459%	+$140K	﹤0.01%	558
2026 Q1	$31.9K	Buy	+162	New	+$31.2K	﹤0.01%	1024

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capula Management's AZN Position: Q2 2026 in Review

Capula Management increased its AstraZeneca (AZN) stake by 459% in Q2 2026, buying an estimated $140K and bringing the position to 905 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #558.

Capula Management first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Capula Management held 905 shares of AstraZeneca worth $172K as of Q2 2026.
Capula Management bought 743 AstraZeneca shares in Q2 2026, an estimated $140K.
AstraZeneca made up ﹤0.01% of Capula Management's portfolio in Q2 2026, its #558 holding.
Capula Management first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Capula Management's 13F filing for Q2 2026, filed 14 Aug 2026.